Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$66.60 USD

66.60
1,644,379

+0.71 (1.08%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

BioMarin (BMRN) could produce exceptional returns because of its solid growth attributes.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View

by Zacks Equity Research

BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.

BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 68.42% and 7.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -3.45% and 9.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the second quarter of 2024 in both the United States and International segments.

Can Amgen (AMGN) Keep the Beat Streak Alive in Q2 Earnings?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings

by Zacks Equity Research

Evaluate the expected performance of BioMarin (BMRN) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its second-quarter earnings release, given the absence of a marketed product.

Perrigo (PRGO) to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical

by Zacks Equity Research

Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.

Ekta Bagri headshot

Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More

by Ekta Bagri

Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.

Why BioMarin (BMRN) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release

by Zacks Equity Research

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xoma (XOMA) Surges 6.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Is The Options Market Predicting A Spike In BioMarin Pharmaceutical (BMRN) Stock?

by Zacks Equity Research

Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand

by Zacks Equity Research

BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks Worth Adding to Your Portfolio in 2024

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.